NasdaqGS - Nasdaq Real Time Price USD
BioNTech SE (BNTX)
At close: November 20 at 4:00 PM EST
Pre-Market: 9:21 AM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 7 | 16 | 18 |
| Avg. Estimate | 0.53 | -1.96 | -3.04 | -3.4 |
| Low Estimate | -1.19 | -3.03 | -4.99 | -7.52 |
| High Estimate | 2.1 | -1.23 | -1.42 | -0.06 |
| Year Ago EPS | 1.9 | -1.31 | 3.83 | -3.04 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 5 | 17 | 19 |
| Avg. Estimate | 1.15B | 217.65M | 2.61B | 2.61B |
| Low Estimate | 853.66M | 145M | 2.4B | 1.81B |
| High Estimate | 1.75B | 310.9M | 2.77B | 3.46B |
| Year Ago Sales | 1.48B | 187.6M | 3.82B | 2.61B |
| Sales Growth (year/est) | -22.40% | 16.02% | -31.78% | 0.05% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 2.45 | -1.35 | -2.04 | -1.61 |
| EPS Actual | 1.9 | -1.31 | -3.36 | 0.81 |
| Difference | -0.55 | 0.04 | -1.32 | 2.42 |
| Surprise % | -22.45% | 2.86% | -64.44% | 150.43% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.53 | -1.96 | -3.04 | -3.4 |
| 7 Days Ago | 0.54 | -2 | -2.9 | -3.43 |
| 30 Days Ago | 3.12 | -2.07 | -2.54 | -3.15 |
| 60 Days Ago | 2.95 | -2.04 | -2.41 | -2.74 |
| 90 Days Ago | 3.39 | -2.06 | -2.22 | -2.65 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | -- |
| Up Last 30 Days | 1 | 1 | 3 | 3 |
| Down Last 7 Days | -- | 3 | 2 | 2 |
| Down Last 30 Days | 9 | 3 | 11 | 10 |
Growth Estimates
| CURRENCY IN USD | BNTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -72.17% | -- | -- | 5.00% |
| Next Qtr. | -49.39% | -- | -- | 12.00% |
| Current Year | -179.36% | -- | -- | 2.10% |
| Next Year | -11.77% | -- | -- | 12.20% |
Upgrades & Downgrades
| Upgrade | Evercore ISI Group: In-Line to Outperform | 11/19/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/18/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/14/2024 |
| Upgrade | Goldman Sachs: Neutral to Buy | 11/8/2024 |
| Maintains | TD Cowen: Hold to Hold | 11/6/2024 |
Related Tickers
MRNA Moderna, Inc.
36.94
-0.94%
NVAX Novavax, Inc.
8.06
+0.75%
REGN Regeneron Pharmaceuticals, Inc.
743.35
-0.17%
VRTX Vertex Pharmaceuticals Incorporated
451.23
+0.72%
NTLA Intellia Therapeutics, Inc.
13.12
-7.15%
VKTX Viking Therapeutics, Inc.
51.53
+0.04%
SMMT Summit Therapeutics Inc.
18.62
-6.90%
INCY Incyte Corporation
71.05
+0.69%
CRSP CRISPR Therapeutics AG
47.26
+0.62%
ALNY Alnylam Pharmaceuticals, Inc.
248.79
+6.20%